Schuppli R, Dressler H, Yawalkar S J, Weirich E G
Z Hautkr. 1983 Feb 15;58(4):230-7.
In a multicenter controlled study carried out in Austria and Switzerland by 8 dermatologists in 208 patients with acute eczematous dermatoses, 0.05% halometasone cream proved to have significantly superior clinical efficacy than 0.05% betamethasone dipropionate cream (P much less than 0.05) showing an equal tolerability. Good to very good results were reported in 93% of the patients treated with halometasone and in 84% of those treated with betamethasone dipropionate creams (Diprosone, Diproderm). General tolerability of both treatments was good. Neither skin atrophy nor any systemic adverse effect, due to the transcutaneous absorption of the corticoids, were observed in this study.
在奥地利和瑞士由8位皮肤科医生对208例急性湿疹性皮炎患者开展的一项多中心对照研究中，0.05%卤米松乳膏被证明临床疗效显著优于0.05%丙酸倍他米松乳膏（P远小于0.05），且耐受性相当。使用卤米松治疗的患者中有93%报告疗效良好至非常好，使用丙酸倍他米松乳膏（得宝松、特美肤）治疗的患者中有84%报告疗效良好至非常好。两种治疗的总体耐受性良好。本研究中未观察到因皮质类固醇经皮吸收导致的皮肤萎缩或任何全身不良反应。
